US 7737265
RNAi modulation of HIF-1 and therapeutic uses thereof
granted A61PA61P11/00A61P11/06
Quick answer
US patent 7737265 (RNAi modulation of HIF-1 and therapeutic uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 10 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jun 15 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 10 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P17/06, A61P19/02